Voyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Ecor1 Capital, Llc Purchases 376,000 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Rating) major shareholder Ecor1 Capital, Llc acquired 376,000 shares of the business’s stock in a transaction dated Thursday, June 23rd. The shares were bought at an average cost of $5.66 per share, with a total value of $2,128,160.00. Following the transaction, the insider now directly owns 4,753,907 shares of the company’s stock, valued at approximately $26,907,113.62. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ecor1 Capital, Llc also recently made the following trade(s):

  • On Tuesday, June 21st, Ecor1 Capital, Llc acquired 101,400 shares of Voyager Therapeutics stock. The shares were bought at an average cost of $5.28 per share, with a total value of $535,392.00.

NASDAQ:VYGR traded up $0.88 during mid-day trading on Thursday, hitting $5.84. The company’s stock had a trading volume of 776,624 shares, compared to its average volume of 619,604. Voyager Therapeutics, Inc. has a fifty-two week low of $2.46 and a fifty-two week high of $10.60. The company has a market capitalization of $224.58 million, a price-to-earnings ratio of -2.83 and a beta of 1.10. The stock has a fifty day moving average of $6.53 and a 200-day moving average of $5.22.

Voyager Therapeutics (NASDAQ:VYGRGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). Voyager Therapeutics had a negative return on equity of 76.83% and a negative net margin of 224.48%. The business had revenue of $0.66 million during the quarter, compared to analyst estimates of $28.25 million. Sell-side analysts expect that Voyager Therapeutics, Inc. will post -1.71 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of VYGR. EcoR1 Capital LLC acquired a new stake in shares of Voyager Therapeutics during the third quarter worth approximately $1,173,000. Walleye Capital LLC acquired a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $1,148,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Voyager Therapeutics by 359.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 147,534 shares of the company’s stock worth $400,000 after buying an additional 115,404 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Voyager Therapeutics by 241.2% during the first quarter. Goldman Sachs Group Inc. now owns 113,560 shares of the company’s stock valued at $865,000 after purchasing an additional 80,277 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Voyager Therapeutics by 620.2% during the first quarter. Bank of America Corp DE now owns 87,867 shares of the company’s stock valued at $669,000 after purchasing an additional 75,666 shares during the last quarter. 46.16% of the stock is owned by institutional investors.

A number of research analysts have recently commented on the stock. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 30th. Chardan Capital upped their price objective on shares of Voyager Therapeutics from $4.00 to $6.00 in a research report on Wednesday, March 9th.

Voyager Therapeutics Company Profile (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Read More

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.